Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: open surgery Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

NCT00608959
View directory record Official record
Conditions
Infection
Interventions
omiganan 1% gel, chlorhexidine 2% solution
Drug
Lead sponsor
Cadence Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Mobius® Post-cesarean Pain Randomized Control Trial

NCT00685932
View directory record Official record
Conditions
Complications; Cesarean Section, Pregnancy
Interventions
Mobius Retractor
Device
Lead sponsor
Abbey Hardy-Fairbanks
Other
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery

NCT00617552
View directory record Official record
Conditions
Postoperative Ileus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 24, 2026, 4:47 AM EDT
Terminated Not applicable Interventional Results available

Secondary Versus Tertiary Wound Closure in High Risk Gynecologic Abdominal Surgical Incisions

NCT03861065
View directory record Official record
Conditions
Surgical Incision
Interventions
Tertiary Wound Closure, Historical Wound Closure
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Completed No phase listed Observational

A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study

NCT01916733
View directory record Official record
Conditions
Glycemic Control, Surgical Site Infections, Cardiac Complications, Length of Stay, Cost
Interventions
standard insulin protocol post-op (continuous IV insulin)
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 24, 2026, 4:47 AM EDT
Active, not recruiting No phase listed Observational

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787
View directory record Official record
Conditions
Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions
Balfaxar, Kcentra
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
3,574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Active, not recruiting Not applicable Interventional

Randomized Trial of EUS-guided Gastrojejunostomy and Surgical Gastrojejunostomy in Gastric Outlet Obstruction

NCT05548114
View directory record Official record
Conditions
Gastric Outlet Obstruction
Interventions
EUS-guided gastrojejunostomy, Surgical gastrojejunostomy
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 24, 2026, 4:47 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
51
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

NCT04228445
View directory record Official record
Conditions
Ureter Injury
Interventions
3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%, Saline spray
Drug
Lead sponsor
Prove pharm
Industry
Eligibility
18 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

NCT04238481
View directory record Official record
Conditions
Laparoscopic/Minimally Invasive Colorectal Surgery
Interventions
Pudexacianinium chloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Orlando, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 24, 2026, 4:47 AM EDT
Not listed No phase listed Observational

International Register of Open Abdomen

NCT02382770
View directory record Official record
Conditions
Open Abdomen Procedure
Interventions
Open abdomen procedure
Procedure
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 24, 2026, 4:47 AM EDT
Terminated Not applicable Interventional

SCP vs HUSLS for Pelvic Organ Prolapse Repair

NCT02800512
View directory record Official record
Conditions
Pelvic Organ Prolapse, Cystocele, Rectocele, Enterocele
Interventions
Robotic sacrocolpopexy, high uterosacral ligament suspension
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Not listed Phase 1Phase 2 Interventional

Biomarker Study: Heart Failure Patients at Risk

NCT05336175
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Angiotensin 1-7, Saline solution
Drug
Lead sponsor
University of Arizona
Other
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

NCT00071968
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 24, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT05879250
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, STAT3 Inhibitor WP1066, Surgical Procedure
Procedure · Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical

NCT01940523
View directory record Official record
Conditions
Osteoarthritis
Interventions
Topical Tranexamic Acid, Intravenous Tranexamic Acid
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 100 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 24, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Fitness and Strength in Postoperative Cardiac Patients Undergoing Exercise Therapy: Biological and Functional Mechanisms of Recovery

NCT04903691
View directory record Official record
Conditions
Cardiorespiratory; Insufficiency, Due to A Procedure, Long-Term, Cardiac Surgery
Interventions
Cardiac Exercise Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 24, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax
Drug · Procedure
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT07416188
View directory record Official record
Conditions
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor, Glioblastoma Multiforme, Recurring Glioblastoma, Brain and Central Nervous System Tumors, Glioma, Glioblastomas, Grade IV Astrocytoma, GBM, Recurrent Glioma (Glioblastoma Multiforme), High Grade Glioma, Glioma, Malignant, Brain Cancer
Interventions
LMP744, Conventional Surgery or Biopsy
Drug · Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Completed No phase listed Observational

An Open Label Data Collection Study of My Connect Post-Op, a Post-Operative Communication Tool

NCT07120191
View directory record Official record
Conditions
Total Hip Replacement, Total Knee Replacement
Interventions
post op communication software
Device
Lead sponsor
Concentra AI, inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Wichita, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 24, 2026, 4:47 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

NCT07646210
View directory record Official record
Conditions
Advanced Heart Failure, Ischemic Heart Failure
Interventions
HiCM-188 Cells
Drug
Lead sponsor
HELP Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 24, 2026, 4:47 AM EDT